Amylyx Pharmaceuticals, Inc. Unrecorded Unconditional Purchase Obligation, to be Paid, Year One
Amylyx Pharmaceuticals, Inc. (AMLX) had Unrecorded Unconditional Purchase Obligation, to be Paid, Year One of $13.60 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Unconditional Purchase Obligations (Excluding Capital Stock Redemptions)
us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary · last filed 2026-08-06
- 2026-06-30: Unrecorded Unconditional Purchase Obligation, to be Paid, Year One $13.60M.
| Period end | Unrecorded Unconditional Purchase Obligation, to be Paid, Year One |
|---|---|
| 2026-06-30 | $13.60M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |